Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.

@article{Kim2017OnceweeklyAO,
  title={Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.},
  author={Albert M Kim and Veena R Somayaji and Jennifer Q. Dong and Timothy P. Rolph and Yan Weng and Jeffrey R. Chabot and Kathryn E Gropp and Saswata Talukdar and Roberto A Calle},
  journal={Diabetes, obesity & metabolism},
  year={2017},
  volume={19 12},
  pages={
          1762-1772
        }
}
AIMS To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analogue, in obese people with hypertriglyceridaemia on atorvastatin, with or without type 2 diabetes. METHODS Participants received PF-05231023 or placebo intravenously once weekly for 4 weeks. Safety (12-lead ECGs, vital signs, adverse events [AEs], laboratory tests) and longitudinal weight assessments were performed. Blood samples were collected… CONTINUE READING
4 Citations
25 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 25 references

of Health and Human Services; National Institutes of Health; National Heart L, and Blood Institute

  • U. S. Departmen
  • Your guide to lowering your cholesterol with TLC…
  • 2016

Similar Papers

Loading similar papers…